Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment

2013 ◽  
Vol 141 (1) ◽  
pp. 79-88 ◽  
Author(s):  
Tuomas Heikkinen ◽  
Taina Korpela ◽  
Rainer Fagerholm ◽  
Sofia Khan ◽  
Kristiina Aittomäki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Translation Initiation ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Chemotherapy Treatment ◽  
Eukaryotic Translation ◽  
Cancer Tumor ◽  
Eukaryotic Translation Initiation ◽  
Tumor Phenotype ◽  
Anthracycline Chemotherapy

scholarly journals Differential expression of eukaryotic translation initiation factor 4E-binding protein 2 in cancers of the breast.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Translation Initiation ◽  
Normal Breast ◽  
Translation Initiation Factor ◽  
Differentially Expressed ◽  
Initiation Factor ◽  
Primary Tumors ◽  
Eukaryotic Translation ◽  
Eukaryotic Translation Initiation

Breast cancer affects women at relatively high frequency (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding eukaryotic translation initiation factor 4E-binding protein 2, EIF4EBP2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. EIF4EBP2 was also differentially expressed in lymph node metastasis in human breast cancer. EIF4EBP2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of EIF4EBP2 in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal B and HER2+ subtype cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by PAM50 molecular subtype. EIF4EBP2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.

scholarly journals N1-Guanyl-1,7-Diaminoheptane Sensitizes Estrogen Receptor Negative Breast Cancer Cells to Doxorubicin by Preventing Epithelial-Mesenchymal Transition through Inhibition of Eukaryotic Translation Initiation Factor 5A2 Activation

2015 ◽  
Vol 36 (6) ◽  
pp. 2494-2503 ◽  
Author(s):  
Yu Liu ◽  
Rongrong Liu ◽  
Peifen Fu ◽  
Feiya Du ◽  
Yun Hong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Translation Initiation ◽  
Breast Cancer Cells ◽  
Epithelial Mesenchymal Transition ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Mesenchymal Transition ◽  
Eukaryotic Translation ◽  
Eukaryotic Translation Initiation

Background: Approximately 30% of breast cancer does not express the estrogen receptor (ER), which is necessary for endocrine-based therapy approaches. Many studies demonstrated that eukaryotic translation initiation factor 5A2 (eIF5A2) serves as a proliferation-related oncogene in tumorigenic processes. Methods: The present study used cell viability assays, EdU incorporation assays, western blot, and immunofluorescence to explore whether N1-guanyl-1,7-diaminoheptane (GC7), which inhibits eIF5A2 activation, exerts synergistic cytotoxicity with doxorubicin in breast cancer. Results: We found that GC7 enhanced doxorubicin cytotoxicity in ER-negative HCC1937 cells but had little effect in ER-positive MCF-7 and Bcap-37 cells. Administration of GC7 reversed the doxorubicin-induced epithelial-mesenchymal transition (EMT) in ER-negative breast cancer cells. Knockdown of eIF5A2 by siRNA inhibited the doxorubicin-induced EMT in ER-negative HCC1937 cells. Conclusion: These data demonstrated that GC7 combination therapy may enhance the therapeutic efficacy of doxorubicin in estrogen negative breast cancer cells by preventing EMT through inhibition of eIF5A2 activation.

scholarly journals Differential expression of the eukaryotic translation initiation factor EIF1B in the brain metastases of patients with breast cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Brain Metastases ◽  
Differential Expression ◽  
Translation Initiation ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Eukaryotic Translation Initiation Factor ◽  
Eukaryotic Translation ◽  
Eukaryotic Translation Initiation ◽  
The Brain

Metastasis to the brain is a complication of breast cancer (1, 2) with limited treatment options (3). We mined published microarray data (4, 5) to discover genes associated with brain metastases in patients with metastatic breast cancer. We identified significant differential expression of the eukaryotic translation initiation factor EIF1B in the brain metastases of patients with breast cancer as compared to primary tumors of the breast. EIF1B may be relevant to the underlying biology by which tumor cells of the breast spread to the brain.

Sign in / Sign up

Export Citation Format

Share Document